AstraZeneca builds targeted cancer drug portfolio
AstraZeneca is building out a portfolio of targeted cancer drugs, and the first pivotal readout from its wholly owned antibody-drug conjugates is a win: sonesitatug vedotin (Sone-Ve) reduced the risk of death by 42% in previously treated advanced gastric cancer in a phase 3 trial. The drug is one part of a broader AstraZeneca push […] The post AstraZeneca builds targeted cancer drug portfolio appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Original Source
Read the full article at Beckershospitalreview →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.